The Trump administration would need to finalize the proposed Medicare and Medicaid rule before it would take effect.
The Biden administration is looking to extend Medicare and Medicaid coverage to include obesity drugs like Wegovy and Zepbound. Weight loss drugs are now excluded from mandatory coverage.
President Joe Biden has proposed expanding Medicare and Medicaid coverage for anti-obesity drugs to over 7 million Americans.
Shares of weight-loss drugmakers Novo Nordisk and Eli Lilly rose on Tuesday after U.S. President Joe Biden proposed expanding ...
If made official, the proposed rule would give Part D and Medicaid beneficiaries expanded coverage to antiobesity drugs ...
Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by ...
The proposed rule could give millions of Americans access to the new drugs; it will also put pressure on the incoming Trump administration.
CMS proposes changes to Medicare and Medicaid to cover weight-loss drugs, recognizing obesity as a disease. This could expand ...
The Biden administration’s latest proposal to allow Medicare and Medicaid to cover weight loss drugs such as Ozempic and ...
The plans from the Department of Health and Human Services come on the heels of criticism Ozempic and other weight loss medications received by RFK Jr.
Proposal would let patients get Wegovy, Ozempic, related drugs for obesity, which is not a covered condition now.
Biden administration's proposal to have popular weight-loss drugs like Wegovy or Ozempic covered by Medicare or Medicaid.